Results Healthcare is pleased to announce that it advised SERB Specialty Pharmaceuticals on its acquisition of Veriton Pharma.
This transaction highlights our exceptional track record in advising fast-growth private equity-backed businesses in the pharmaceutical sector.
SERB is a leading European specialty pharmaceutical group focused on prescription medicines that address rare and lifethreatening diseases and is backed by Charterhouse Capital Partners, one of the longest established private equity firms operating in Europe.
Founded in 1997, Veriton is a private pharmaceutical company specialising in the development of licensed and unlicensed medicines for patients with special requirements, with offices in the UK, Middle East and Australia.
The acquisition of Veriton takes the total number of add-on acquisitions made by SERB to five since November 2017, bringing SERB’s total products to around 80. During this period, SERB has transformed into a true pan-European player with direct presence in nine European countries, which will now be complemented by Veriton’s presence across the Middle East and Australia. SERB has made 50 new hires over the last two years and, following the integration Veriton, the Company’s team will be 110 strong.
“Results Healthcare was very supportive throughout the process with its strong sectorial expertise”
ARTHUR PIGNOT, M&A AND BUSINESS DEVELOPMENT VP AT SERB SPECIALTY PHARMACEUTICALS